$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

2021-04-02

2024-04

2024-04

3

Study Overview

The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer

Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.

This is a single arm, open-label, single-center study.This study is indicated for advanced relapse-refractory or metastatic pancreatic cancer.The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. Primary objective is to explore the safety, main consideration is dose-related safety.

  • Advanced Pancreatic Cancer
  • DRUG: Adoptive TIL-TCM transfer therapy
  • 2022DZKY-039-02

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-06-26  

N/A  

2022-06-29  

2022-06-29  

N/A  

2022-06-30  

2022-06-30  

N/A  

2022-06  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: adoptive TIL-TCM transfer

TIL-TCM cells are isolated from the patients' Tumor tissue (or ascites) and peripheral blood obtained before standard chemotherapy and then cultured ex-vivo. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the

DRUG: Adoptive TIL-TCM transfer therapy

  • Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
Primary Outcome MeasuresMeasure DescriptionTime Frame
Dose-limiting toxicity (DLT)To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancerBaseline up to 28 days after TIL-TCM cells infusion
Maximum Tolerated Dose（MTD）To evaluate the Safety and Effectiveness of specific TIL-TCM cells in the Treatment of patients with advanced relapse-refractory or metastatic pancreatic cancerBaseline up to 28 days after TIL-TCM cells infusion
incidence of adverse events( AE )and Serious adverse events(SAE)Adverse events assessed according to NCI-CTCAE v5.0 criteria.up to 72 weeks after TIL-TCM cells infusion
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Overall response rate (ORR)ORR is defined as the percentage of patients who have a clinical response (objective tumor regression).ORR is computed by: the sum of the number of patients with Complete Response (CR) and number of patients with Partial Response (PR) / total number of patients. The total number of patients is the sum of the number of patients with CR, PR, stable disease (SD) or progressive disease (PD). The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) is used as the criteria to determine whether a tumor disappears (CR), shrinks (PR), stays the same (SD) or gets bigger (PD).18 months
Duration of response (DOR)DOR is the time between the initial response to treatment per RECIST v1.1 and subsequent disease progression among patients achieving Complete Response (CR) or Partial Response (PR). RECIST v1.1 is used as the criteria to determine whether a tumor disappears (CR) or shrinks (PR).18 months
Progression-free survival (PFS)PFS is the length of time from the date patient enrolled in to the date on which tumor progresses or the patient dies for any cause.18 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Xinbo Wang, MD

Phone Number: 13505172912

Email: wxinbo2008@163.com

Study Contact Backup

Name: Sizhen Wang, MD

Phone Number: 15195900565

Email: wsizhen@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Aged≥18 years old and ≤70 years old when signing the informed consent; regardless of gender;Body weight>40kg. 2. Patients with advanced recurrent refractory or metastatic pancreatic cancer who have failed at least one standard treatment or who are unable to tolerate, unwilling or financially unable to receive standard treatment. 3. The subject will have at least one eligible tissue or sample available for cell preparation. 4. Patients with brain metastatic lesions who are asymptomatic , the diameter of a single lesion ≤1 cm, and the number of lesions ≤3 may be eligible. 5. Patients should have good clinical presentation status (ECOG 0 or 1). 6. HIV antibody and treponema pallidum antibody was negative. 7. Vital organ function test (do not accept any cytokines or blood transfusion within 14 days prior to test):
    1)absolute neutrophil count (ANC) ≥1000/μL; 2)White blood cell count (WBC) 3000/μL; 3)Platelet count (PLT) 75,000 /μL; 4)Hemoglobin (Hb) > 8.0 g/dL; 5) Coagulation: activated partial thromboplastin time (APTT) ≤1.5×ULN, international normalized ratio (INR) or Prothrombin time (PT)≤1.5×ULN; 6) Liver functions: alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤5.0 ×ULN; 7) Liver functions:Total bilirubin (TBIL)<1.5×ULN (baseline value normal); <1.0 - 1.5×ULN( baseline value abnormal); If diagnosed as Gilbert syndrome, ≤3.0 mg/dL; The test results should prevail of the center laboratory ; 8)Renal function: eGFR>60 mL/min or 6-24 hours CrCl>60 mL/min; 9)Heart Doppler ultrasound:LVEF≥50%;
    8.Non-surgically sterilized women of child-bearing age are required to consent to use at least one medically approved contraceptive method during the study and one year after completion.Women of child-bearing age must be negative for pregnancy test at 7 days before initiation of the treatment.Male subjects must agree to use medically approved contraception from the time they sign the informed consent form to the time they leave the study.
    9.Expected survival no less than 3 months.
    Exclusion Criteria:
    1. Pregnancy or lactation; 2. Active infections requiring systemic anti-infective therapy ( topical antibiotics excepted); 3. Patients who are taking systemic steroids or immunosuppressive drugs; 4. Hepatitis B (hepatitis B surface antigen [HbsAg] and/or core antibody [HbcAb] positive, HBV-DNA<1000 copies /mL can be included); 5. Hepatitis C ( HCV antibody positive and HCV-RNA positive); 6. Serious autoimmune diseases or immunodeficiency disease, such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE) and autoimmune vasculitis (eg., Wegener's granulomatosis); 7. Allergic:Severe allergies to the drugs used in the study; Contraindications for IL-2 used ; 8. Patients with other active malignancies within the past 5 years, but not those who were clinically cured within 5 years of diagnosis of cervical epithelial carcinoma, basal or squamous skin cancer, superficial bladder cancer, breast cancer in situ and did not require follow-up; 9. Any mental diseases, including dementia and changes in mental status that may influence the understanding about the informed consent and questionnaire; 10. Unstable disease of heart head blood-vessel, including but not limited to, the heart cerebrovascular accident or transient ischemic (within 6 months prior to screening) myocardial infarction (within 6 months prior to screening)/vein thrombosis (within 6 months prior to screening, require surgery to repair the aortic aneurysm or proximal artery thrombosis group shall not enter into) unstable angina New York Heart Association (NYHA) Classification≥ III congestive heart failure severe arrhythmias poorly controlled by medications and severe hypertension that cannot be controlled by treatment or is untreated (systolic pressure≥160 mmHg and/or diastolic pressure≥100 mmHg ); 11. Patients with severe interstitial pneumonia other active pneumonia or bronchospasm and other respiratory diseases that seriously affect lung function; 12. Patients with active gastrointestinal bleeding; 13. Had major surgery within 1 month prior to screening or during the study ; 14. Enrolled in other clinical trials (including other adoptive cell immunotherapies) and used the investigational drug within 1 month prior to screening. 15. Have received live attenuated vaccine within 1 month prior to screening or are expected to receive live attenuated vaccine during the study ; 16. Received any systemic antitumor drug therapy (including chemotherapy, radiotherapy, molecular targeted therapy, immunotherapy or other biotherapy) within 4 weeks prior to pretreatment; 17. Have previously received allogeneic bone marrow transplantation or solid organ transplantation; 18. Alcohol, drug or substance abuse; 19. Judged as serious uncontrollable diseases by the researchers, or other conditions that may interfere with the treatment and therefore being ineligible.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • Shanghai Biomed-union Biotechnology Co., Ltd.
  • STUDY_DIRECTOR: Xinbo Wang, MD, Jinling Hospital,Nanjing University

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate